Spectral AI, Inc. filings document an emerging growth medical-diagnostics company developing the DeepView System for AI-driven wound-care and burn assessment. Its 8-K reports cover financial results, BARDA funding announcements, Regulation FD disclosures, executive appointments, compensation arrangements and changes in senior leadership.
Proxy materials describe director elections, auditor ratification, shareholder voting matters and Nasdaq-related share issuance authorization. The filing record also identifies the company’s capital structure, including common stock and redeemable warrants listed on Nasdaq, and provides formal disclosure of governance actions, material agreements, operating updates and public-company reporting status.
Spectral AI, Inc. (Nasdaq: MDAI) is registering and offering 3,065,000 shares of common stock at $1.90 per share in a registered direct offering. The company expects net proceeds of approximately $5.1 million after fees and expenses and plans to use the funds for working capital and general corporate purposes.
In a concurrent private placement, the company is also selling pre-funded warrants to purchase up to 935,000 shares at an exercise price of $0.0001 per share and warrants to purchase up to 4,000,000 shares at an exercise price of $2.51 per share; these securities and their underlying shares are not registered here. Northland Securities, Inc. is acting as sole placement agent on a reasonable best efforts basis. Shares outstanding were 27,623,895 as of October 22, 2025, and are expected to be 30,688,895 after this offering. The company cites public float of approximately $52.1 million and states current S-3 capacity under General Instruction I.B.6 to offer up to approximately $11.1 million.